Dataset Information

Further validation of the Amblyopia Treatment Index parental questionnaire.

ABSTRACT: The Amblyopia Treatment Index (ATI) is a parental questionnaire that has been used to assess the impact of patching or atropine treatment on the child and family in several amblyopia treatment studies. The 18-item parental questionnaire was designed with versions for treatment with patching or atropine. We pooled data across studies to further evaluate the validity of the ATI, to further assess the presence or absence of factors (subscales).A parent or guardian completed the ATI for 794 children who participated in 1 of 4 randomized clinical trials. Internal consistency reliability was assessed with Cronbach's alpha, and factor analysis was performed.The ATI demonstrated high internal consistency reliability, with a Cronbach's alpha of 0.88 (95% CL = 0.87, 0.89). Factor analysis revealed the same 3 minimally overlapping factors found in the original validation study, which were again labeled "adverse effects," "treatment compliance," and "social stigma." Two of the 18 items did not load with any factor and could reasonably be omitted from future ATI administrations.The ATI is a useful instrument for assessing the impact of patching or atropine treatment on the child and family.

SUBMITTER: Holmes JM

PROVIDER: S-EPMC2692740 | biostudies-literature | 2008 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Further validation of the Amblyopia Treatment Index parental questionnaire.

Holmes Jonathan M JM Strauber Samara S Quinn Graham E GE Cole Stephen R SR Felius Joost J Kulp Marjean M

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 20081030 6

<h4>Background</h4>The Amblyopia Treatment Index (ATI) is a parental questionnaire that has been used to assess the impact of patching or atropine treatment on the child and family in several amblyopia treatment studies. The 18-item parental questionnaire was designed with versions for treatment with patching or atropine. We pooled data across studies to further evaluate the validity of the ATI, to further assess the presence or absence of factors (subscales).<h4>Methods</h4>A parent or guardian ...[more]

PMID: 18976946

Similar Datasets

Project description:BackgroundAmblyopia is a visual condition that occurs in childhood. Screening programmes exist within the United Kingdom (UK) to detect amblyopia, and once detected treatment is given.Existing patient reported outcome (PRO) measures for amblyopia do not meet current recommendations for the methods adopted during their development, or the way in which the instruments are administered. The overall aim of this study was to produce a self-complete PRO instrument for amblyopia for children aged 4-7 years that uses children's responses in the development phase. The study comprised a number of stages. This paper reports on the refinement of the descriptive system for the draft instrument (the Child Amblyopia Treatment Questionnaire, CAT-QoL) using qualitative and quantitative methods.MethodsThe study consisted of three components. Children were asked to read, and complete the draft questionnaire as independently as possible. They were then asked about the questionnaire, and its format, in a cognitive debriefing exercise. Observations were made as to the child's ability to read the questionnaire, particular attention was made as to which individual words participants struggled to read. Children were also asked their opinion on the design layout of the questionnaire. Finally, some children were asked to complete a ranking task to help determine the order of the levels of the items as judged by the children. Mid-rank scoring and statistical level of agreement were calculated for the ranking exercise.ResultsThirty-two (n=32) participants completed a draft questionnaire; each of these underwent a cognitive de-briefing interview. Twenty-two (n=22) children completed the ranking exercise. Ten children did not understand the concept of ranking. The results of the qualitative phase (cognitive de-briefing interview) were used to modify the wording of items and layout of the instrument. Results of the ranking exercise were used to inform the order of the response levels for the items.ConclusionResponses of young children can be used in the development of PRO instruments. They are able to help inform the content, wording, and format of an instrument, ensuring good content and face validity. The results have been used to further refine the CAT-QoL, however further research is required to assess the psychometric properties of the instrument.

Project description:ObjectiveTo develop and validate a new scale to assess treatment burden (the effort of looking after one's health) for patients with multimorbidity.DesignMixed-methods.SettingUK primary care.ParticipantsContent of the Multimorbidity Treatment Burden Questionnaire (MTBQ) was based on a literature review and views from a patient and public involvement group. Face validity was assessed through cognitive interviews. The scale was piloted and the final version was tested in 1546 adults with multimorbidity (mean age 71 years) who took part in the 3D Study, a cluster randomised controlled trial. For each question, we examined the proportion of missing data and the distribution of responses. Factor analysis, Cronbach's alpha, Spearman's rank correlations and longitudinal regression assessed dimensional structure, internal consistency reliability, construct validity and responsiveness, respectively. We assessed interpretability by grouping the global MTBQ scores into zero and tertiles (>0) and comparing participant characteristics across these categories.ResultsCognitive interviews found good acceptability and content validity. Factor analysis supported a one-factor solution. Cronbach's alpha was 0.83, indicating internal consistency reliability. The MTBQ score had a positive association with a comparator treatment burden scale (rs 0.58, P<0.0001) and with self-reported disease burden (rs 0.43, P<0.0001), and a negative association with quality of life (rs-0.36, P<0.0001) and self-rated health (rs-0.36, P<0.0001). Female participants, younger participants and participants with mental health conditions were more likely to have high treatment burden scores. Changes in MTBQ score over 9-month follow-up were associated, as expected, with changes in measures of quality of life (EuroQol five dimensions, five level questionnaire) and patient-centred care (Patient Assessment of Chronic Illness Care).ConclusionThe MTBQ is a 10-item measure of treatment burden for patients with multimorbidity that has demonstrated good content validity, construct validity, reliability and responsiveness. It is a useful research tool for assessing the impact of interventions on treatment burden.Trial registration numberISRCTN06180958.

Dataset Information

Further validation of the Amblyopia Treatment Index parental questionnaire.

Publications

Further validation of the Amblyopia Treatment Index parental questionnaire.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure